PLG

Chr 6ADAR

plasminogen

Also known as: HAE4

The plasminogen protein encoded by this gene is a serine protease that circulates in blood plasma as an inactive zymogen and is converted to the active protease, plasmin, by several plasminogen activators such as tissue plasminogen activator (tPA), urokinase plasminogen activator (uPA), kallikrein, and factor XII (Hageman factor). The conversion of plasminogen to plasmin involves the cleavage of the peptide bond between Arg-561 and Val-562. Plasmin cleavage also releases the angiostatin protein which inhibits angiogenesis. Plasmin degrades many blood plasma proteins, including fibrin-containing blood clots. As a serine protease, plasmin cleaves many products in addition to fibrin such as fibronectin, thrombospondin, laminin, and von Willebrand factor. Plasmin is inactivated by proteins such as alpha-2-macroglobulin and alpha-2-antiplasmin in addition to inhibitors of the various plasminogen activators. Plasminogen also interacts with plasminogen receptors which results in the retention of plasmin on cell surfaces and in plasmin-induced cell signaling. The localization of plasminogen on cell surfaces plays a role in the degradation of extracellular matrices, cell migration, inflamation, wound healing, oncogenesis, metastasis, myogenesis, muscle regeneration, neurite outgrowth, and fibrinolysis. This protein may also play a role in acute respiratory distress syndrome (ARDS) which, in part, is caused by enhanced clot formation and the suppression of fibrinolysis. Compared to other mammals, the cluster of plasminogen-like genes to which this gene belongs has been rearranged in catarrhine primates. [provided by RefSeq, May 2020]

Primary Disease Associations & Inheritance

Angioedema, hereditary, 4MIM #619360
AD
DysplasminogenemiaMIM #217090
AR
Plasminogen deficiency, type IMIM #217090
AR
554
ClinVar variants
52
Pathogenic / LP
0.01
pLI score
12
Active trials
Clinical SummaryPLG
🧬
Gene-Disease Validity (ClinGen)
hypoplasminogenemia · ARDefinitive

Definitive — sufficient evidence for diagnostic panels

Population Constraint (gnomAD)
Constrained for loss-of-function variants (OE-LoF 0.28) despite low pLI — interpret in context.
📋
ClinVar Variants
52 Pathogenic / Likely Pathogenic· 259 VUS of 554 total submissions
💊
Clinical Trials
12 active or recruiting trials — potential therapeutic options may be available

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Moderate LoF intolerance
LoF Constraint?LOEUF (Loss-of-function Observed/Expected Upper bound Fraction) is the upper bound of the 90% CI for LoF OE — the preferred gnomAD v4 metric. Lower = more intolerant to LoF. LOEUF < 0.35 = highly constrained.
0.44LOEUF
pLI 0.010
Z-score 4.57
OE 0.28 (0.180.44)
Moderately constrained

More LoF-intolerant than ~75% of genes

Missense Constraint?Missense Z-score: standard deviations fewer missense variants observed vs. expected. Z > 3.09 (p < 0.001) = gene does not tolerate missense variation. OE missense < 0.6 is also considered constrained.
0.21Z-score
OE missense 0.97 (0.901.05)
434 obs / 446.7 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios?Shaded band = 90% confidence interval. Vertical tick = point estimate. Grey threshold line = gnomAD constraint cutoff for that variant class.
LoF OE?Ratio of observed to expected LoF variants. Upper CI bound (LOEUF) ≤ 0.35 = strong LoF constraint signal.0.28 (0.180.44)
00.351.4
Missense OE?Ratio of observed to expected missense variants. OE ≤ 0.6 = fewer missense variants than expected by chance.0.97 (0.901.05)
00.61.4
Synonymous OE?Control metric — synonymous variants are largely neutral and expected near OE = 1.0. Significant deviation may indicate annotation issues.1.09
01.21.6
LoF obs/exp: 13 / 46.7Missense obs/exp: 434 / 446.7Syn Z: -0.93

ClinVar Variant Classifications

554 submitted variants in ClinVar

Classification Summary

Pathogenic41
Likely Pathogenic11
VUS259
Likely Benign153
Benign76
Conflicting14
41
Pathogenic
11
Likely Pathogenic
259
VUS
153
Likely Benign
76
Benign
14
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
2
6
33
0
41
Likely Pathogenic
6
2
3
0
11
VUS
0
226
27
6
259
Likely Benign
0
5
62
86
153
Benign
0
7
60
9
76
Conflicting
14
Total8246185101554

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

PLG · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

OMIM — Genotype-Phenotype Relationships

1 OMIM entry

PLASMINOGEN; PLG
MIM #173350 · *

Angioedema, hereditary, 4

MIM #619360

Molecular basis of disorder known

Autosomal dominant

Dysplasminogenemia

MIM #217090

Molecular basis of disorder known

Autosomal recessive

Plasminogen deficiency, type I

MIM #217090

Molecular basis of disorder known

Autosomal recessive
Clinical Literature
Landmark / reviewRecent case evidence

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

ALS (Amyotrophic Lateral Sclerosis)

This Study Evaluates the Safety, Target Engagement, and Preliminary Efficacy of Galunisertib (TGF-βR1/ALK5 Inhibitor)Combined With Nerandomilast (PDE4 Inhibitor) in GREM2-positive ALS, a Biomarker-defined Subgroup Hypothesized to Reflect Heightened TGF-β/SMAD-driven Astrocytic and Fibrotic Signaling

NOT YET RECRUITING
NCT07321860Phase PHASE2, PHASE3Gipfel Life Sciences GmbHStarted 2026-06-30
Galunisertib + Nerandomilast Combination
IBS - Irritable Bowel Syndrome

Comparison Between Low FODMAP and SSRD in IBS

ENROLLING BY INVITATION
NCT05192603Phase NARegion SkaneStarted 2022-03-01
low FODMAP or SSRD
HypertriglyceridemiaNormal

Cardiometabolic Properties of Omega-3 Functionalized With Hydroxytyrosol

ACTIVE NOT RECRUITING
NCT06992323Phase NANational Research Council, SpainStarted 2025-02-17
EPA + HTEPASunflower Oil
Obese Patients (BMI ≥ 30 kg/m²)AnxietyDepressive Disorder

Therapeutic Potential of a Synbiotic to Improve Mental Health in Subjects With Obesity.

RECRUITING
NCT06901739Phase NACelia BañulsStarted 2025-04-15
SynbioticPlacebo
Polycystic Ovary SyndromeHypothalamic Amenorrhea

Body Fat as Determinant of Female Gonadal Dysfunction

RECRUITING
NCT03841981Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y CajalStarted 2020-01-31
Anthropometric and physical examinationIndirect calorimetry, accelerometer and seven-day dietary recallBiochemical, hormonal and metabolic phenotyping
Diabetes Mellitus, Type 1Inflammation

The Role of the Adrenergic System in Hypoglycaemia Induced Inflammatory Response in People With Type 1 Diabetes and People Without Type 1 Diabetes-RAID-II

ACTIVE NOT RECRUITING
NCT06422494Phase NARadboud University Medical CenterStarted 2025-01-01
hyperinsulinaemic hypoglycaemic clampPropranolol Hydrochloride 1 MG/MLPhentolamine
Plasminogen Deficiency

Study of Individuals Affected With Hypoplasminogenemia

RECRUITING
NCT03797495Indiana Hemophilia &Thrombosis Center, Inc.Started 2018-12-18
Acute-On-Chronic Liver FailureAlcoholic HepatitisLiver Cirrhosis, Alcoholic

A-TANGO Phase 2 Study

NOT YET RECRUITING
NCT06890039Phase PHASE2Yaqrit LtdStarted 2025-09-01
PlaceboTAK-242G-CSF (Filgrastim)
Relapsing Remitting Multiple Sclerosis (RRMS)

Indole-3-PROpionic Acid Clinical Trials - Multiple Sclerosis

RECRUITING
NCT07318129Phase NAGlostrup University Hospital, CopenhagenStarted 2026-01-26
PlaceboIndole-3-propionic acid (IPA)
HealthyConstipation

Dairy Products to Your Gut and Brain

RECRUITING
NCT06311097Phase NAUniversity of CopenhagenStarted 2024-04-08
Fermented dairyNon-fermented dairy
Heart Failure

Acute Reno-Cardiac Action of Dapagliflozin In Advanced Heart Failure Patients on Heart Transplant Waiting List

RECRUITING
NCT06868797Phase NACentral Hospital, Nancy, FranceStarted 2025-08-29
Biological sample for the measurement of suPAR levels.
Metastatic Thyroid Gland CarcinomaUnresectable Thyroid Gland Carcinoma

Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery

ACTIVE NOT RECRUITING
NCT01947023Phase PHASE1National Cancer Institute (NCI)Started 2013-09-27
Biopsy ProcedureBiospecimen CollectionComputed Tomography